Document Type : Original Article


1 Department of Microbiology, Faculty of Basic Sciences, Islamic Azad University, Tehran Pishva Branch, Varamin, Iran

2 Department of Microbiology, Faculty of Basic Sciences, Islamic Azad University, North Tehran Branch, Tehran, Iran


Due to the increasing level of bacterial antibiotic resistance (AB), it is now required to modify the dosage for customized medication using therapeutic drug monitoring. The creation of a novel treatment for clinical use, such as situations of bacterial resistance, has been hailed as a feasible, affordable, and quick alternative by the pharmaceutical industry. Therefore, the current research sought to examine the myorelaxant Thiocolchicosidum's antibacterial activity against bacterial strains. Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, Proteus mirabilis ATCC 25933, and Pseudomonas aeruginosa ATCC 27853 were used as the bacteria in an in vitro experimental study, along with the protocols for antibacterial activity screening, minimum inhibitory concentration (MIC), and characterization of antibacterial activity. Thiocolchicosidum, at levels varying from 0.48 to 1000 µg/mL, was the chemical. The only bacterial strains that showed any sensitivity to the myorelaxant were E. coli and P. aeruginosa, both of which had MICs of 500 µg/mL and 1000 µg/mL, respectively. Thiocolchicosidum demonstrated a bacteriostatic effect in the antimicrobial characterization test. Therefore, despite the fact that this medication is already considered safe for human use, no discernible antibacterial effects were shown in common bacterial strains. Therefore, research is required to determine how it differs from other microbes, such as various kinds of bacteria, fungus, and protozoa, in order to rule it out as a potential antibiotic material for use in industry.


1.Garzón V, Bustos RH, G. Pinacho D. Personalized medicine
for antibiotics: the role of nanobiosensors in therapeutic
drug monitoring. Journal of Personalized Medicine. 2020;Sep 25;10(4):147.
2.Arredondo A, Blanc V, Mor C, Nart J, León R. Resistance
to β-lactams and distribution of β-lactam resistance
genes in subgingival microbiota from Spanish patients
with periodontitis. Clinical oral investigations. 2020;
3.Chang HH, Cohen T, Grad YH, Hanage WP, O’Brien
TF, Lipsitch M. Origin and proliferation of multiple-
drug resistance in bacterial pathogens. Microbiology and
Molecular Biology Reviews. 2015 ;Mar;79(1):101-16.
4.O’Neill J. Review on antimicrobial resistance.
Antimicrobial resistance: tackling a crisis for the health
and wealth of nations. 2014 ;Dec 11;2014(4).
5.Asadipour E, Asgari M, Mousavi P, piri gharaghie T,
Ghajari G, Mirzaei A. Nano‐Biotechnology and challenges
of drug delivery system in cancer treatment pathway.
Chemistry & Biodiversity. 2023; Mar 1:e202201072.
6.Taghiloo S, Ghajari G, Zand Z, Kabiri-Samani S, Kabiri H,
Rajaei N, Piri-Gharaghie T. Designing Alginate/Chitosan
Nanoparticles Containing Echinacea angustifolia: A
Novel Candidate For Combating Multidrug‐resistant
Staphylococcus aureus. Chemistry & Biodiversity. 2023;
May 9:e202201008.
7.Piri Gharaghie T, Doosti A, Mirzaei SA. Prevalence
and antibiotic resistance pattern of Acinetobacter spp.
infections in Shahrekord medical centers. Developmental
Biology. 2021 ;Nov 22;13(4):35-46.
8.Piri Gharaghie T, Sadat Shandiz SA, Beiranvand S.
Evaluation of silver nanoparticles effects on bla-per1 gene
expression for biofilm formation in isolates of antibiotic-
resistant Acientobacter Bumanni by real time PCR
method. Cellular and Molecular Research (Iranian Journal
of Biology). 2022 ;Jun 22;35(2):349-66.
9.Reeves D, Lovering A, Thomson A. Therapeutic drug
monitoring in the past 40 years of the Journal of
Antimicrobial Chemotherapy. Journal of Antimicrobial
Chemotherapy. 2016; Dec 1;71(12):3330-2.
10.Piri Gharaghie T, Sadat Shandiz SA. The inhibitory
effects of silver nanoparticles on bap gene expression in
antibiotic-resistant acientobacter bumanni isolates using
real-time PCR. Journal of Ilam University of Medical
Sciences. 2018 ;Nov 15;26(4):175-85.
11.Garzón V, Pinacho DG, Bustos RH, Garzón G, Bustamante
S. Optical biosensors for therapeutic drug monitoring.
Biosensors. 2019 ;Nov 11;9(4):132.
12.Mabilat C, Gros MF, Nicolau D, Mouton JW, Textoris
J, Roberts JA, Cotta MO, van Belkum A, Caniaux I.
Diagnostic and medical needs for therapeutic drug
monitoring of antibiotics. European Journal of Clinical
Microbiology & Infectious Diseases. 2020; May;39:791-7.
13.Fadeel B, Garcia-Bennett AE. Better safe than sorry:
Understanding the toxicological properties of inorganic
nanoparticles manufactured for biomedical applications.
Advanced drug delivery reviews. 2010 Mar 8;62(3):362-
14.Hoyos P, Pace V, Alcántara AR. Biocatalyzed synthesis
of statins: A sustainable strategy for the preparation of
valuable drugs. Catalysts. 2019; Mar 14;9(3):260.
15.Bastos ML, Tavaziva G, Abidi SK, Campbell JR, Haraoui
LP, Johnston JC, Lan Z, Law S, MacLean E, Trajman A,
Menzies D. Diagnostic accuracy of serological tests for
covid-19: systematic review and meta-analysis. bmj. 2020
Jul 1;370.
16.Majumder MA, Rahman S, Cohall D, Bharatha A,
Singh K, Haque M, Gittens-St Hilaire M. Antimicrobial
stewardship: Fighting antimicrobial resistance and
protecting global public health. Infection and drug
resistance. 2020; Dec 29:4713-38.
17.Ghajari G, Nabiuni M, Amini E. The association between
testicular toxicity induced by Li2Co3 and protective effect
of Ganoderma lucidum: Alteration of Bax & c-Kit genes
expression. Tissue and Cell. 2021; Oct 1;72:101552.
18.Ghimpețeanu OM, Pogurschi EN, Popa DC, Dragomir
N, Drăgotoiu T, Mihai OD, Petcu CD. Antibiotic use in
livestock and residues in food—A public health threat: A
review. Foods. 2022; May 16;11(10):1430.
19.Gracheva IA, Shchegravina ES, Schmalz HG, Beletskaya
IP, Fedorov AY. Colchicine alkaloids and synthetic
analogues: current progress and perspectives. Journal of
medicinal chemistry. 2020; May 20;63(19):10618-51.
20.Alhmied F, Alammar A, Alsultan B, Alshehri M, Pottoo
FH. Molecular mechanisms of thymoquinone as anticancer
agent. Combinatorial Chemistry & High Throughput
Screening. 2021; Nov 1;24(10):1644-53.
21.Souod N, Kargar M, Doosti A, Ranjbar R, Sarshar M.
Genetic analysis of cagA and vacA genes in Helicobacter
pylori isolates and their relationship with gastroduodenal
diseases in the west of Iran. Iranian Red Crescent Medical
Journal. 2013; May;15(5):371.
22.Azadbakht N, Doosti A, Jami MS. CRISPR/Cas9-mediated
LINC00511 knockout strategies, increased apoptosis of
breast cancer cells via suppressing antiapoptotic genes.
Biological procedures online. 2022 ;Dec;24(1):1-5.
23.Raghunath D. Emerging antibiotic resistance in bacteria
with special reference to India. Journal of biosciences.
2008 ;Nov;33(4):593-603.
24.Hadera M, Mehari S, Basha NS, Amha ND, Berhane
Y. Study on antimicrobial potential of selected non-
antibiotics and its interaction with conventional antibiotics.
Pharmaceutical and Biosciences Journal. 2018 ; Jan 23:01-
25.Tong Z, Zhang L, Ling J, Jian Y, Huang L, Deng D. An
in vitro study on the effect of free amino acids alone or in
combination with nisin on biofilms as well as on planktonic
bacteria of Streptococcus mutans. PloS one. 2014 ; Jun
26.Kargar M, Mohammadalipour Z, Doosti A, Lorzadeh S,
Japoni-Nejad A. High prevalence of class 1 to 3 integrons
among multidrug-resistant diarrheagenic Escherichia coli
in southwest of Iran. Osong public health and research
perspectives. 2014; Aug 1;5(4):193-8.
27.Ortega‐Rojas MA, Castillo E, Razo‐Hernández RS, PastorN, Juaristi E, Escalante J. Effect of the Substituent and
Amino Group Position on the Lipase‐Catalyzed Resolution
of γ‐Amino Esters: A Molecular Docking Study Shedding
Light on Candida antarctica lipase B Enantioselectivity.
European Journal of Organic Chemistry. 2021 Sep
14;2021; (34):4790-802.
28.Huczyński A, Rutkowski J, Popiel K, Maj E, Wietrzyk J,
Stefańska J, Majcher U, Bartl F. Synthesis, antiproliferative
and antibacterial evaluation of C-ring modified colchicine
analogues. European Journal of Medicinal Chemistry.
2015; Jan 27;90:296-301.
29.Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y, Huang
C. Overcoming cancer therapeutic bottleneck by drug
repurposing. Signal transduction and targeted therapy.
2020 Jul 2;5(1):113.
30.Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB.
Cancer drug discovery by repurposing: teaching new tricks
to old dogs. Trends in pharmacological sciences. 2013
;Sep 1;34(9):508-17.